Glenmark launches authorized generic of Savella (milnacipran hydrochloride tablets) in the U.S., targeting a $102.9 million fibromyalgia treatment market.
Written By: Vennela Reddy, BPharm
Reviewed By: Pharmacally Editorial Team
Glenmark Pharmaceuticals Inc., USA has announced the launch of Milnacipran Hydrochloride Tablets in strengths of 12.5 mg, 25 mg, 50 mg, and 100 mg in the United States. The product is an authorized generic version of Savella®, a treatment widely prescribed for fibromyalgia.
Milnacipran hydrochloride is a serotonin–norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and sleep disturbances. The launch expands Glenmark’s portfolio of complex and specialty generics in the U.S. market.
According to IQVIA sales data for the 12-month period ending January 2026, the Savella tablet market across these strengths generated approximately $102.9 million in annual sales, highlighting a significant opportunity for generic competition.
Commenting on the launch, Marc Kikuchi, President and Business Head for North America at Glenmark, said the introduction of Milnacipran Hydrochloride Tablets reinforces the company’s strategy to bring quality and affordable treatment alternatives to patients while expanding its presence in the U.S. generics market.
With this launch, Glenmark continues to strengthen its North American generics portfolio, focusing on products that improve accessibility to established therapies while maintaining supply reliability in the U.S. healthcare system.
References
Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg, 19 March 2026, https://glenmarkpharma.com/gpl_pdfs/media/Press%20Release%20-%20Glenmark%20launches%20Authorized%20Generic%20to%20Milnacipran%20Hydrochloride%20Tablets.pdf
About the Writer
Vennela Reddy, B.Pharm is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publishable and scientific content development. Along with this she also interested in wellness and healthcare writing due to her natural interest in those topics. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.